Sylentis People in the News: Phillip Maples, Catherine Moukheibir Premium Gradalis has promoted Phillip Maples as executive vice president and chief technical officer. Sylentis Preps to Move Glaucoma Drug into Phase II Next Year Premium This article has been updated to correct details regarding SYL1001's development timeline. IP Update: Recent Patents, Patent Applications Awarded to Sylentis, Quark, NIH, and More Premium Title: Inducible Small RNA Expression Constructs for Targeted Gene Silencing Patent Number: 8,198,077 Filed: Jan. 15, 2004 Lead Inventor: Thomas Tuschl, Max Plank Institute Sylentis Picks up Option to Alnylam RNAi IP Premium Alnylam Pharmaceuticals said this week that it has granted Sylentis, a Spanish developer of RNAi drugs, a non-exclusive option to license certain of its RNAi-related intellectual property. Sylentis Authorized to Manufacture Drugs for Research Premium The company said the Spanish Agency for Medicines and Healthcare Products has cleared its lab to make pharmaceutical compounds for research. Sep 9, 2010 Sylentis Cleared to Begin Phase I/II Trial of Ocular Hypertension Drug Premium Jul 8, 2010 Sylentis Concludes Phase Ia Study of Glaucoma Drug Premium Apr 29, 2010 Key RNAi-Based Drugs in the Clinic: April 2010 Premium Apr 1, 2010 Sylentis Eyes Second Part of Phase I/II Trial for Glaucoma Rx, Searches for Partners Premium Nov 12, 2009 Key RNAi-Based Drugs in the Clinic Premium Aug 20, 2009 Sylentis Aims to Begin Phase I Study of Glaucoma Drug in September Premium Feb 19, 2009 Spain's Sylentis Looks to Move siRNA-Based Glaucoma Drug into Phase I This Year Premium Breaking News IndyGeneUS AI Acquires Genetic Cryptocurrency Creator EncrypGen Analysis Estimates Psychiatric Disorder Risk from Specific Copy Number Variants in Danish Cohort Proteomic Profiling With Two Platforms Provides Complementary Gene, Protein, Phenotype Links Centogene Reports 17 Percent Drop in Q3 Revenues, Closing Down COVID Testing Business StageZero Raising C$4.2M in Private Placement of Stocks, Warrants NGeneBio Gets CE-IVD Mark for HLA Typing Assay The Scan Comfort of Home The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity. Keep Under Control Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says. Just Make It The New York Times writes that there is increased interest in applying gene synthesis to even more applications. Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.